Get to know our developments
KeyZell focuses on the development of first-line anticancer compounds that induce apoptosis (programmed death) of cancer cells. To do this, we seek to bring our team’s promising research into the human clinical phase, developing a new future for oncology, thanks to innovative new therapies that address today’s unmet medical needs.
The first drug candidate is set to begin clinical trials as a first-line therapy for non-small cell lung cancer.
It is also developing the innovative KEYZELL PAHO AI system, which aims to be the future of precision medicine in oncology, choosing personalized treatments for cancer patients who do not respond to traditional treatments, offering the most appropriate option for cancer, in the right order and at the ideal time according to the characteristics of each patient.
Want to know more?
We lead the Precision Medicine biomedical revolution
This represents a huge opportunity for both patients and the sector in terms of economics and innovation